An interventional study of Zidovudine in HIV Infections, sponsored by Glaxo Wellcome. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Glaxo Wellcome · Not applicable, Interventional, and Treatment
To assess the efficacy of Retrovir (AZT) therapy in the treatment of HIV Ab positive persons with impairments in neuropsychological functioning. To assess the safety, virologic, and immunologic effects of AZT therapy in HIV Ab positive persons with neuropsychological impairment but minimal other symptomatology.
4,258 studies on the registry are indexed under HIV Infections; 240 are open to participants now.
Browse HIV Infections studies →Glaxo Wellcome is the lead sponsor of 72 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
Concurrent Medication:
Excluded:
Patients with the following are excluded:
Prior Medication:
Excluded:
Prior Treatment:
Excluded within 3 months of study entry:
Impaired performance on a defined neuropsychological test battery.
History of drug or alcohol abuse.
This study is completed, as verified in Feb 1995. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glaxo Wellcome